Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Mechanistic evaluation of thymol in a rat model of methotrexate-induced intestinal injury: NF-κB, Nrf2/HO-1, PPARγ/SIRT1, and RIPK1/RIPK3/MLKL pathways.

El-shaimaa A. Arafa, Gaber F. Ali, Emad H. M. Hassanein et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24172

e24172 Background: Thymol is a monoterpene phenol with numerous pharmacological properties, including antibacterial, antit...

Postoperative adjuvant therapy of donafenib in hepatocellular carcinoma with high-risk recurrence factors: A real world, prospective, observational study.

Changzhen Shang, Jinyi Zhong, Xuan Luo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16268

e16268 Background: The five-year recurrence rate of hepatocellular carcinoma (HCC) after hepatic resection is as high as 7...

Diagnostic yield after pre-biopsy steroid administration in primary CNS high-grade B-cell lymphoma.

Charmi Trivedi, Ryan Snow, Chanjun Park et al. Jun 01, 2026 pp. 7056-7056 10.1200/jco.2026.44.16_suppl.7056

7056 Background: Primary central nervous system high-grade B-cell lymphoma (PCNSL) is typically diagnosed via brain biopsy...

Interpretable machine learning to identify health system levers for survival outcomes of patients with prostate cancer.

Edward Christopher Dee, Milit S. Patel, Frederic Ivan L. Ting et al. Jun 01, 2026 pp. 1595-1595 10.1200/jco.2026.44.16_suppl.1595

1595 Background: Global disparities in prostate cancer outcomes are among the most pronounced across all cancer types. Whi...

Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non–small cell lung cancer.

Loïc Ferrer, Ernest Nadal, Thibaut Dejean et al. Jun 01, 2026 pp. 8022-8022 10.1200/jco.2026.44.16_suppl.8022

8022 Background: Pathological complete response (pCR) after neoadjuvant chemoimmunotherapy is associated with improved out...

Predicting treatment effect on distant recurrence free survival from functional tumor volume change during neoadjuvant therapy: A Bayesian hierarchical model of I-SPY 2 MRI and survival data.

Keli Siqueiros Santos-Parker, Jessica Santos-Parker, Wen Li et al. Jun 01, 2026 pp. 618-618 10.1200/jco.2026.44.16_suppl.618

618 Background: In neoadjuvant cancer trials, early endpoints that predict treatment effect on survival identify promising...

Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with <i>STK11</i> , <i>KEAP1</i> , and/or <i>KRAS</i> mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.

Ferdinandos Skoulidis, Hossein Borghaei, Edward B. Garon et al. Jun 01, 2026 pp. 8515-8515 10.1200/jco.2026.44.16_suppl.8515

8515 Background: Pts with STK11 , KEAP1 an...

IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.

George Au-Yeung, Mathias Bressel, Yi-An Ko et al. Jun 01, 2026 pp. 5587-5587 10.1200/jco.2026.44.16_suppl.5587

5587 Background: Cyclin E1 ( CCNE1 ) gene amplification and protein over-expressio...

ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.

Jose Pablo Leone, Kathryn Jean Ruddy, Naim Rashid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps656

TPS656 Background: Male breast cancer is a rare disease, and most cases are hormone receptor-positive (HR+). Due to a lack...

Bone health and antiresorptive agent use in Asian American Pacific Islander (AAPI) women with breast cancer.

Stacey Pan, Jayant Y. Gadrey, Hocine Tighiouart et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12696

e12696 Background: AAPI women with breast cancer (BC) may be at increased risk for poor bone health due to lower bone mine...

Unintended access barriers: How upper payment limit implementation may risk patient access.

Julie Patterson, Roswell Cole, Jonathan D. Campbell Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23053

e23053 Background: Four states currently operate prescription drug affordability boards (PDABs) with purported authority t...

A phase 2 multi-center pharmacodynamic study of the fatty acid synthase (FASN) inhibitor TVB-2640 in advanced <i>KRAS</i> -mutant non–small cell lung cancer.

Arthi Sridhar, Jennifer Leddon, Ang Gao et al. Jun 01, 2026 pp. 3079-3079 10.1200/jco.2026.44.16_suppl.3079

3079 Background: Preclinical and translational studies demonstrate that KRAS-mutant NSCLC has a unique metabolic dependenc...

PTPRZ1–MET fusion and induction of reprogrammed immuno-microenvironment via MET–IFN-β–LGALS9 signaling pathway during IDH-mutant glioma progression.

Zhaoshi Bao, Chengjun Zheng, Qiaodong Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14088

e14088 Background: Recurrent IDH-mutant high-grade gliomas are difficult to treat, with limited effective targeted or immu...

National trends and disparities in cancer-related mortality among adults with diabetes in the U.S., 1999–2023.

Abaan Merchant, Muhammad Bin Salman, Omar Hamadi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21003

e21003 Background: The prevalence of diabetes in the U.S. has nearly doubled, contributing to increased cancer risk due to...

Phase I study of the LiViT regimen (liposomal irinotecan, vincristine, and temozolomide) in pediatric patients with relapsed/refractory solid tumors.

Feifei Sun, Yizhuo Zhang, Suying Lu et al. Jun 01, 2026 pp. 10039-10039 10.1200/jco.2026.44.16_suppl.10039

10039 Background: Relapsed or refractory solid tumors in children and adolescents remain a major therapeutic challenge wit...

First-in-human PET imaging of <sup>68</sup> Ga-FC516, a novel ACP3-targeted radiotracer for prostate cancer.

Kongzhen Hu, Ruitao Yang, Lu Wang et al. Jun 01, 2026 pp. 5128-5128 10.1200/jco.2026.44.16_suppl.5128

5128 Background: Prostatic acid phosphatase (ACP3) is overexpressed in more than 85% of prostate cancers, and largely abse...

IFCT-2401 SPORADIC trial: Integrating cemiplimab to sequential hypofractionated chemoradiotherapy for unfit or elderly patients with unresectable stage III non–small cell lung cancer.

Sébastien Thureau, Judith Raimbourg, Nicolas Pourel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8128

TPS8128 Background: Patients with unresectable stage III non-small cell lung cancer (NSCLC) who are elderly or have signif...

Extent of resection and survival in <i>IDH</i> -mutant WHO grade 2 glioma: A systematic review and meta-analysis.

Sukhmani Sidhu, Ashish Sharma, Harendra Kumar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14098

e14098 Background: For IDH-mutant WHO grade 2 gliomas, extent of resection (EOR) is thought to improve long-term outcomes,...

Digital health intervention for comorbid insomnia and neurocognitive impairment in adult survivors of childhood cancer: Results from a randomized clinical trial.

Tara M. Brinkman, Kayla Stratton, Chiara Papini et al. Jun 01, 2026 pp. 10003-10003 10.1200/jco.2026.44.16_suppl.10003

10003 Background: Survivors of childhood cancer are at risk of developing both insomnia and cognitive impairment, which ma...

KIF11 as a druggable target in NSCLC: An integrated computational analysis.

Yusuf Acikgoz Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20716

e20716 Background: Non-small cell lung cancer (NSCLC) in non-smoking women represents a biologically distinct subgroup in...

Efficacy and safety of neoadjuvant chemotherapy with AG regimen with or without nimotuzumab in borderline resectable or locally advanced pancreatic cancer: A retrospective cohort study.

Yi Chen Tang, Yonggang He, Aimaiti Yasen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16375

e16375 Background: This study aimed to evaluate whether adding nimotuzumab to an albumin-bound paclitaxel plus gemcitabine...

Prevalence of <i>CDH1</i> germline variants in gastric cancer patients with exome-inferred ancestry.

Skylar Nahi, Richard Green, Shifra Krinshpun et al. Jun 01, 2026 pp. 4073-4073 10.1200/jco.2026.44.16_suppl.4073

4073 Background: Germline pathogenic or likely pathogenic (P/LP) CDH1 variants inc...

Testicular plasmacytoma: A comprehensive case series and review.

Kennedy Kuykendall, Jackson Carr, Haya Safar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19565

e19565 Background: Testicular plasmacytoma (TP) is a rare manifestation of plasma cell neoplasms, occurring alone or with...

Bridging the cardio-oncology care gap in India: Real-world guideline adherence and AI-driven workflow optimization in 2300 breast cancer patients at a tertiary cardiac center.

Sadhu Aishwarya Reddy, Gadugoyyala Guna Sri Phani Ajay, Rishita Verma et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12719

e12719 Background: Cardiotoxic cancer therapies necessitate guideline-recommended cardiac surveillance in breast cancer pa...

A multiple-instance learning-based deep learning model with multi-channel input for early detection of breast tumor.

Hyeong-Gon Moon, Young-Gon Kim, Jinyoung Byeon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12576

e12576 Background: Early detection of breast cancer is essential but remains limited by the high cost. Echo signal–based a...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page